3 recruiting, 2 active not recruiting, 1 completed, 1 not yet recruiting. 4 Phase 2, 2 Phase 1, 2 Phase 3, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Active not recruiting 1, Completed 1 |
| Phase 1 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 2 | Recruiting 2 |
| Early Phase 1 | 1 | Active not recruiting 1 |
Follow Unresectable Gastric Adenocarcinoma: new trials by email Literature Review of Unresectable Gastric Adenocarcinoma trials Research Report on Unresectable Gastric Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Biospecimen Collection, Computed Tomography, Futibatinib - Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Phase 1 | Not yet recruiting | Northwestern University | 18 | 2027-09-09 | 2026-10-20 |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 224 | 2024-06-24 | 2026-10-21 |
| A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer AgenT-797, Botensilimab, Balstilimab - Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2024-02-01 | 2026-05-15 |
| mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma Fluorouracil, Leucovorin Calcium, Oxaliplatin - Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 382 | 2023-01-31 | 2026-10-02 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma Lenvatinib, Pembrolizumab - Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2022-02-14 | 2026-07-16 |
| Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer Berzosertib, Computed Tomography Assisted Biopsy, Endoscopic Biopsy - Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2020-11-16 | 2026-10-20 |
Adenocarcinoma Of Esophagus (4) · Carcinoma, Hepatocellular (1) · Carcinoma, Lobular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Carcinosarcoma (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1)
Digestive System Diseases (2) · Digestive System Neoplasms (2) · Head and Neck Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2) · Adenocarcinoma (1) · Breast Diseases (1) · Breast Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Squamous Cell (1) · DNA Virus Infections (1) · Esophageal Diseases (1)
Magnetic Resonance Spectroscopy (5) · Paclitaxel (3) · Ramucirumab (3) · Specimen Handling (3) · Biopsy (2) · Irinotecan (2) · Nivolumab (2) · Taxes (2) · pembrolizumab (2) · Colony-Stimulating Factors (1) · Cyclophosphamide (1) · Endoscopic Mucosal Resection (1) · Endoscopy (1) · Fluorouracil (1) · Immunoglobulin G (1)
National Cancer Institute (NCI) (2) · Alliance for Clinical Trials in Oncology (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1) · Northwestern University (1)
United States (7) · Puerto Rico (1)
Anwaar Saeed (1) · Gladys Rodriguez, MD (1) · Jordan D Berlin (1) · Mariela Blum (1) · Yanyan Lou, MD, PhD (1) · Yelena Janjigian, MD (1)
P30CA060553 (1), U10CA180888 (1), UM1CA186689 (1)